London, UK – March 14, 2024
Relation Therapeutics, a biotechnology company at the forefront of computational and experimental drug discovery, has announced a $35 million seed financing round, bringing its total seed funding to $60 million. The round was led by DCVC and co-led by NVentures, the venture capital arm of NVIDIA, with additional participation from Magnetic Ventures, Khosla Ventures, Abcam founder Jonathan Milner, ARK Invest, and Deerfield Management Company.
Advancing AI-Powered Drug Discovery
“This funding validates our AI-driven approach to drug discovery,” said David Roblin, CEO of Relation Therapeutics.
“With this capital, we will accelerate the discovery of novel biology, targets, and medicines to address critical unmet needs.”
Relation’s Lab-in-the-Loop™ platform combines artificial intelligence, single-cell analysis, and genomics to deliver precise disease mapping and enable discovery of new therapeutic targets.
Investor Perspectives
“Relation is defining the future of techbio by combining world-class datasets with advanced AI models to guide drug discovery,” said Jason Pontin, General Partner at DCVC.
“Generative AI is transforming drug design, and Relation is leading the charge,” added Mohamed Siddeek, Head of NVentures.
Focus on Osteoporosis and Beyond
Relation is currently developing treatments for osteoporosis, a condition affecting over 45 million people worldwide. As part of this effort, the company has launched Osteomics, the world’s largest functional single-cell bone atlas.
“This investment fuels our ability to harness AI and machine learning, including LLMs adapted for biology, to accelerate new therapies,” said Charles Campbell Roberts, Co-founder and Chair of Relation Therapeutics.
About Relation Therapeutics
Relation Therapeutics is a biotechnology company developing innovative therapies for diseases with high unmet medical need. Its proprietary AI-powered Lab-in-the-Loop™ platform integrates:
- Human genetics
- Single-cell multi-omics
- Functional assays
- Machine learning
The company’s pipeline spans metabolic and immune diseases. To date, Relation has raised over $80 million from investors including DCVC, Magnetic, GSK, NVIDIA NVentures, Hitachi Ventures, Khosla, ARK Ventures, and Deerfield.
More about Relation Therapeutics news
By